Details for Patent: 11,097,007
✉ Email this page to a colleague
Which drugs does patent 11,097,007 protect, and when does it expire?
Patent 11,097,007 protects ABILIFY ASIMTUFII and is included in one NDA.
This patent has sixty-five patent family members in thirty-one countries.
Summary for Patent: 11,097,007
| Title: | Injectable preparation |
| Abstract: | An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 sand having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s, as measured. |
| Inventor(s): | Kaneko Daiki, Matsuda Takakuni, Hoshika Yusuke |
| Assignee: | OTSUKA PHARMACEUTICAL CO., LTD. |
| Application Number: | US17108939 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,097,007
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-001 | Apr 27, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ⤷ Try a Trial | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-001 | Apr 27, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Try a Trial | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-002 | Apr 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF SCHIZOPHRENIA | ⤷ Try a Trial | |||
| Otsuka | ABILIFY ASIMTUFII | aripiprazole | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 217006-002 | Apr 27, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,097,007
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 090776 | ⤷ Try a Trial | |||
| Argentina | 126033 | ⤷ Try a Trial | |||
| Australia | 2013253374 | ⤷ Try a Trial | |||
| Australia | 2017228608 | ⤷ Try a Trial | |||
| Australia | 2019200060 | ⤷ Try a Trial | |||
| Australia | 2020204200 | ⤷ Try a Trial | |||
| Australia | 2022241491 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
